vs
Apellis Pharmaceuticals, Inc.（APLS）与Oil-Dri Corp of America（ODC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Oil-Dri Corp of America的1.7倍（$199.9M vs $120.5M），Oil-Dri Corp of America净利率更高（12.8% vs -29.5%，领先42.3%），Oil-Dri Corp of America同比增速更快（-5.8% vs -5.9%），Oil-Dri Corp of America自由现金流更多（$1.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
美国Oil-Dri公司是专业吸附剂及黏土基产品生产商，主营工业溢油清理吸附材料、猫砂等宠物护理产品、农业土壤改良剂及运动场场地调理材料，客户覆盖北美及全球多个商业领域。
APLS vs ODC — 直观对比
营收规模更大
APLS
是对方的1.7倍
$120.5M
营收增速更快
ODC
高出0.1%
-5.9%
净利率更高
ODC
高出42.3%
-29.5%
自由现金流更多
ODC
多$15.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
6.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $120.5M |
| 净利润 | $-59.0M | $15.5M |
| 毛利率 | — | 29.5% |
| 营业利润率 | -25.6% | 14.1% |
| 净利率 | -29.5% | 12.8% |
| 营收同比 | -5.9% | -5.8% |
| 净利润同比 | -62.2% | -5.6% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSODC
| Q4 25 | $199.9M | $120.5M | ||
| Q3 25 | $458.6M | $125.2M | ||
| Q2 25 | $178.5M | $115.5M | ||
| Q1 25 | $166.8M | $116.9M | ||
| Q4 24 | $212.5M | $127.9M | ||
| Q3 24 | $196.8M | $113.7M | ||
| Q2 24 | $199.7M | $106.8M | ||
| Q1 24 | $172.3M | $105.7M |
净利润APLSODC
| Q4 25 | $-59.0M | $15.5M | ||
| Q3 25 | $215.7M | $13.1M | ||
| Q2 25 | $-42.2M | $11.6M | ||
| Q1 25 | $-92.2M | $12.9M | ||
| Q4 24 | $-36.4M | $16.4M | ||
| Q3 24 | $-57.4M | $8.5M | ||
| Q2 24 | $-37.7M | $7.8M | ||
| Q1 24 | $-66.4M | $12.4M |
毛利率APLSODC
| Q4 25 | — | 29.5% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 28.6% | ||
| Q1 25 | — | 29.5% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 29.0% | ||
| Q2 24 | — | 28.2% | ||
| Q1 24 | — | 29.3% |
营业利润率APLSODC
| Q4 25 | -25.6% | 14.1% | ||
| Q3 25 | 48.7% | 12.5% | ||
| Q2 25 | -18.6% | 12.0% | ||
| Q1 25 | -50.0% | 15.0% | ||
| Q4 24 | -12.3% | 16.6% | ||
| Q3 24 | -24.0% | 11.3% | ||
| Q2 24 | -14.7% | 9.8% | ||
| Q1 24 | -36.0% | 14.4% |
净利率APLSODC
| Q4 25 | -29.5% | 12.8% | ||
| Q3 25 | 47.0% | 10.4% | ||
| Q2 25 | -23.6% | 10.1% | ||
| Q1 25 | -55.3% | 11.1% | ||
| Q4 24 | -17.1% | 12.8% | ||
| Q3 24 | -29.2% | 7.5% | ||
| Q2 24 | -18.9% | 7.3% | ||
| Q1 24 | -38.5% | 11.7% |
每股收益（稀释后）APLSODC
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $42.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $266.5M |
| 总资产 | $1.1B | $380.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSODC
| Q4 25 | $466.2M | $42.4M | ||
| Q3 25 | $479.2M | $50.5M | ||
| Q2 25 | $370.0M | $36.5M | ||
| Q1 25 | $358.4M | $22.6M | ||
| Q4 24 | $411.3M | $12.5M | ||
| Q3 24 | $396.9M | $23.5M | ||
| Q2 24 | $360.1M | $46.8M | ||
| Q1 24 | $325.9M | $27.8M |
总债务APLSODC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSODC
| Q4 25 | $370.1M | $266.5M | ||
| Q3 25 | $401.2M | $259.1M | ||
| Q2 25 | $156.3M | $246.9M | ||
| Q1 25 | $164.2M | $235.9M | ||
| Q4 24 | $228.5M | $224.0M | ||
| Q3 24 | $237.1M | $210.6M | ||
| Q2 24 | $264.3M | $202.9M | ||
| Q1 24 | $266.7M | $196.0M |
总资产APLSODC
| Q4 25 | $1.1B | $380.7M | ||
| Q3 25 | $1.1B | $391.7M | ||
| Q2 25 | $821.4M | $369.5M | ||
| Q1 25 | $807.3M | $353.7M | ||
| Q4 24 | $885.1M | $350.2M | ||
| Q3 24 | $901.9M | $354.6M | ||
| Q2 24 | $904.5M | $319.2M | ||
| Q1 24 | $831.9M | $296.2M |
负债/权益比APLSODC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $10.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $1.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 1.1% |
| 资本支出强度资本支出/营收 | 0.1% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 0.67× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $50.8M |
8季度趋势，按日历期对齐
经营现金流APLSODC
| Q4 25 | $-14.2M | $10.3M | ||
| Q3 25 | $108.5M | $25.2M | ||
| Q2 25 | $4.4M | $22.7M | ||
| Q1 25 | $-53.4M | $21.4M | ||
| Q4 24 | $19.4M | $10.9M | ||
| Q3 24 | $34.1M | $23.4M | ||
| Q2 24 | $-8.3M | $19.0M | ||
| Q1 24 | $-133.0M | $9.4M |
自由现金流APLSODC
| Q4 25 | $-14.3M | $1.3M | ||
| Q3 25 | $108.3M | $17.1M | ||
| Q2 25 | $4.4M | $16.0M | ||
| Q1 25 | $-53.4M | $16.4M | ||
| Q4 24 | $19.3M | $-1.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | $-8.4M | $10.8M | ||
| Q1 24 | $-133.3M | $1.9M |
自由现金流率APLSODC
| Q4 25 | -7.1% | 1.1% | ||
| Q3 25 | 23.6% | 13.7% | ||
| Q2 25 | 2.5% | 13.8% | ||
| Q1 25 | -32.0% | 14.0% | ||
| Q4 24 | 9.1% | -1.5% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | -4.2% | 10.1% | ||
| Q1 24 | -77.3% | 1.8% |
资本支出强度APLSODC
| Q4 25 | 0.1% | 7.5% | ||
| Q3 25 | 0.0% | 6.5% | ||
| Q2 25 | 0.0% | 5.8% | ||
| Q1 25 | 0.0% | 4.3% | ||
| Q4 24 | 0.0% | 10.0% | ||
| Q3 24 | 0.0% | 7.3% | ||
| Q2 24 | 0.0% | 7.7% | ||
| Q1 24 | 0.2% | 7.1% |
现金转化率APLSODC
| Q4 25 | — | 0.67× | ||
| Q3 25 | 0.50× | 1.93× | ||
| Q2 25 | — | 1.95× | ||
| Q1 25 | — | 1.66× | ||
| Q4 24 | — | 0.67× | ||
| Q3 24 | — | 2.74× | ||
| Q2 24 | — | 2.44× | ||
| Q1 24 | — | 0.76× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ODC
| Cat Litter | $64.6M | 54% |
| Fluids Purification | $26.7M | 22% |
| Agriculturaland Horticultural | $12.9M | 11% |
| Industrialand Sports | $11.6M | 10% |
| Animal Healthand Nutrition | $4.7M | 4% |
